Table 2.

Survival Outcomes

	Historical Controls N = 140	2nd line Ipilimumab N = 189
Median follow-up months, (95% CI)	30.4 (27.9–37.3)	71.2 (70.3–116.5)
1-year survival rates, (95% CI)
Unadjusted	17.1% (11–23%)	34.3% (27–41%)
IPTW-adjusted	17.1% (11–23%)	35.6% (27–43%)
2-year survival rates, (95% CI)
Unadjusted	7.1% (2.9–11%)	20.6% (15–27%)
IPTW-adjusted	7.1% (2.9–11%)	21.1% (14–28%)
3-year survival rates, (95% CI)
Unadjusted	4.7% (1.2–8.2%)	15.2% (9.6–21%)
IPTW-adjusted	4.7% (1.2–8.2%)	14.3% (8.0–21%)